SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Microcide Pharmaceuticals (MCDE)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Czechsinthemail who wrote (52)5/17/1997 9:20:00 PM
From: scaram(o)uche   of 186
 
I like both companies, but I don't own Cubist. Neither has a product in clinicals. Both had planned to enter the clinic this year, but Cubist has not hit that milestone and now is planning on picking a clinical candidate this year. Yes, Microcide has the stronger cash position, as Cubist went ahead with their IPO at a difficult time.

To me, first blush, the companies seem to be doing very different things. Cubist is focused on amino acid charging of tranfer RNA and other parts of the translational machine, whereas MCDE is working with beta-lactams, the eflux pump, and whatever they may find from the functional genomics program. Very, very different creatures.

Rick
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News